Therefore, our findings uncover a molecular mechanism underlying CCL2 overexpression in the cancer cell and suggest that a neutralizing antibody against CCL2 will serve as an effective therapeutic approach for patients with LNMAT1-overexpressing bladder cancers. This evidence concerns the gene CCL2 and urinary bladder cancer.